Cara Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results
Cara Therapeutics, Inc. (NASDAQ: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the fourth quarter and full year ended December 31, 2021.
